NCT03970447

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

RecruitingPHASE2, PHASE3INTERVENTIONAL

Trial Details

Start: 2019-07-30Est. Completion: 2028-06

Enrollment target: 2,250 participants

Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States
University of California, San Diego, La Jolla, California, United States
Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
University of California, Los Angeles, Los Angeles, California, United States
St. Joseph Hospital, Orange, California, United States
University of California, San Francisco, San Francisco, California, United States
Stanford Cancer Center, Stanford, California, United States
University of Colorado Denver, Aurora, Colorado, United States
Yale Cancer Center / Smilow Cancer Hospital*, New Haven, Connecticut, United States
Mayo Clinic Cancer Center, Jacksonville, Florida, United States
Sylvester Comprehensive Cancer Center*, Miami, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Piedmont Atlanta Hospital, Atlanta, Georgia, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
LSU Health Sciences Center - New Orleans, New Orleans, Louisiana, United States

Glioblastoma Multiforme of BrainGliomaGlioblastoma

This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose o…

Tampa, United StatesEst. completion Jun 2027

GliomaGlioblastomas (GBM)High Grade Gliomas

The aim of this clinical trial is to evaluate the safety, preliminary effectiveness, and pharmacokinetic profiles of SM-…

Beijing, ChinaCompleted Apr 22, 2024

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.